This HTML5 document contains 201 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n11http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n8https://scigraph.springernature.com/pub.10.1007/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q47631238
rdf:type
wikibase:Item
schema:description
artículu científicu 2016年学术文章 мақолаи илмӣ artykuł naukowy bài báo khoa học wetenschappelijk artikel artigo científico 2016年學術文章 article scientific 2016年學術文章 artigo científico (publicado na 2016) naučni članak 2016年学术文章 artículo científico publicado en 2016 2016年學術文章 научни чланак 2016년 논문 наукова стаття, опублікована в лютому 2016 научни чланак vetenskaplig artikel vědecký článek научна статия artikull shkencor article scientifique (publié 2016) บทความทางวิทยาศาสตร์ videnskabelig artikel (udgivet 2016) 2016年学术文章 מאמר מדעי 2016年学术文章 vitenskapelig artikkel مقالهٔ علمی 2016年學術文章 scienca artikolo articolo scientifico სამეცნიერო სტატია article científic 2016年学术文章 bilimsel makale teaduslik artikkel vitskapeleg artikkel vedecký článok articol științific 2016年學術文章 ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ مقالة علمية mokslinis straipsnis scientific article 2016 nî lūn-bûn 2016年の論文 سائنسی مضمون научная статья artikulong pang-agham мақолаи илмӣ tieteellinen artikkeli wissenschaftlicher Artikel 2016年學術文章 tudományos cikk επιστημονικό άρθρο գիտական հոդված artigo científico (publicado na 2016)
p:P577
wds:Q47631238-2A07A522-9F27-488C-A7F6-63498A1A7457
wdt:P577
2016-02-20T00:00:00Z
p:P2888
wds:Q47631238-EFD793E4-5998-47DF-AD20-A7B236829502
wdt:P2888
n8:s10637-016-0333-z
p:P2860
wds:Q47631238-FC647F4F-579E-4FB4-B1D5-90B3D2349304 wds:Q47631238-FD11F089-3FC2-4B99-BC32-7C42A2F9FEAF wds:Q47631238-F1D0F351-0B60-4286-9FBF-70BFADA2D17A wds:Q47631238-F7470A95-62A0-42E3-B0AD-B21B0F43D9F4 wds:Q47631238-F83EC7D5-754F-4B30-85EC-418EAEFF0473 wds:Q47631238-1E943E26-5577-4FF5-B598-67562FFB55B5 wds:Q47631238-23EC2C91-BD34-44DC-BA99-5B6B9EB618D5 wds:Q47631238-2B6567E9-BFF3-4FBB-91A3-0598E49F6180 wds:Q47631238-17CC6905-BC62-454C-890A-FAAEDF2AFF1E wds:Q47631238-1AD174F7-DC24-44FA-B00E-85F2BD8293FB wds:Q47631238-1CCC8D3D-84A8-4A71-888A-AC7DE4B38087 wds:Q47631238-123A915D-4FBA-451F-8A59-34E68324BE73 wds:Q47631238-4E599395-AB99-4041-82E5-BB0335639C42 wds:Q47631238-4E7F9C46-505C-4C28-AD99-9FB12AD36949 wds:Q47631238-5CD046DC-9EF2-4F0E-91C3-078CAB96A16C wds:Q47631238-444DB1E6-B196-487D-95C7-BB07D851B974 wds:Q47631238-4A2DAD31-2F39-4AF7-8686-490624474D67 wds:Q47631238-4AC90CFF-6750-4822-9710-19B4D76DB9F7 wds:Q47631238-3C2DF576-FF3E-4818-ADF7-99CC5A2152B4 wds:Q47631238-3D304B82-98A1-4144-99B5-C7DF22439058 wds:Q47631238-3E42024F-D305-49D3-AA4C-FD3FE2578997 wds:Q47631238-3E9F5877-EC0A-46A9-88AB-2420BEEF9BAB wds:Q47631238-2D89AE16-159E-4A8E-9EA5-A025CFB2DC2F wds:Q47631238-2F7576B9-1E57-41FA-B867-67ADCC789750 wds:Q47631238-34B28EEA-BF5B-4CD2-A688-ABDF29790052 wds:Q47631238-7A841CBD-7DD7-4569-8484-C7D57D1C99C1 wds:Q47631238-7B04DC46-8B2B-4984-AF17-1A3EE5F22C3C wds:Q47631238-7F4AF919-DC59-4D1C-AC34-CB331255522B wds:Q47631238-725B34C8-A1A8-4ED5-B9F8-A706471FDA2E wds:Q47631238-72FAA0F4-82D8-4AF5-A3A1-5A58FA0752AA wds:Q47631238-7503EABB-7EC8-4C85-860C-E386C368F372 wds:Q47631238-690B8B98-2B3E-405C-A240-10E717EF1913 wds:Q47631238-6EE75A93-3382-4C2A-8550-68AC393C0A33 wds:Q47631238-6F1D7757-B59F-4237-8341-008FC9CD5900 wds:Q47631238-71641949-7E08-43C0-A031-FBC437E140B5 wds:Q47631238-5E6E5F7C-17AC-4096-90C5-E4CB27F59F4D wds:Q47631238-5F7A872D-68C0-494A-BD28-8F9E1D92A727 wds:Q47631238-63249D49-84BA-4549-B203-D1B95847BC1B wds:Q47631238-E3BEDF37-52EF-4B24-A305-79314254FB20 wds:Q47631238-EA9CD08C-E24C-4392-B2A5-83EE1A22D9E5 wds:Q47631238-D229F086-A764-4286-8018-11C793E64B17 wds:Q47631238-D282E22B-18EE-4BEE-B00B-D5E2958E7CE2 wds:Q47631238-A56F0720-0752-4BE5-BBDD-1B2ADB0AECE4 wds:Q47631238-B7AC8055-2A94-48C2-9F4A-ACCF5EC663A6 wds:Q47631238-C9683B1F-E0BF-4FDD-8AF6-619245E40045 wds:Q47631238-9845D0AB-876D-4D55-966E-93055971D70F wds:Q47631238-9DBBA6B5-36DB-4C4F-8E15-F6DF8E5FD672
wdt:P2860
wd:Q33410240 wd:Q34690946 wd:Q50616468 wd:Q42007942 wd:Q37947708 wd:Q57569718 wd:Q38403603 wd:Q37783289 wd:Q54304708 wd:Q43582734 wd:Q53608936 wd:Q55021320 wd:Q28328220 wd:Q55003539 wd:Q70507914 wd:Q42537725 wd:Q34639876 wd:Q48244765 wd:Q42643499 wd:Q34580719 wd:Q55385218 wd:Q34199968 wd:Q38126819 wd:Q68778289 wd:Q33488674 wd:Q51551095 wd:Q34603983 wd:Q83455932 wd:Q24606920 wd:Q39003233 wd:Q85894498 wd:Q33413862 wd:Q34504714 wd:Q44821289 wd:Q44389304 wd:Q83858912 wd:Q28240554 wd:Q57033225 wd:Q72747507 wd:Q34729354 wd:Q40233201 wd:Q37892375 wd:Q36690873 wd:Q33381250 wd:Q44439070 wd:Q33406103 wd:Q43186637
p:P2093
wds:Q47631238-9405CF1F-CD84-4213-AE82-126C9392B2F6 wds:Q47631238-95C4F8C7-DA50-45AE-A712-224BBC5A269D wds:Q47631238-C7E1B50B-D26E-4443-8757-B290357DFCA9 wds:Q47631238-7B1462DA-184C-4528-8B45-A29119F42A23 wds:Q47631238-49FC00B1-CDDB-405C-B3D8-39EC18D37235 wds:Q47631238-F3CAE6B8-B972-4C2D-80AD-0CBED36453B7 wds:Q47631238-D44DDA06-EA90-407A-9055-4B561AB6A968
wdt:P2093
Launce Gouw Jennifer Wright Debbie Pitt Mark Wade Sunil Sharma Sant Chawla Ken Boucher
rdfs:label
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
skos:prefLabel
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
schema:name
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
p:P50
wds:Q47631238-58F8CBD8-5DED-478A-8C98-96B6C4CF997E
wdt:P50
wd:Q89134921
p:P1476
wds:Q47631238-3957BC2B-87D3-4FC4-BB1A-0ADB7B00BD4E
wdt:P1476
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
p:P304
wds:Q47631238-1E3E98B4-BC14-4C5A-B3C9-F1390D660D0A
wdt:P304
243-252
p:P31
wds:Q47631238-07B65E9F-8F0E-4944-A5FE-AA325B5721A5
wdt:P31
wd:Q13442814
p:P921
wds:Q47631238-E1463FE3-FC2E-442F-B332-E06DCFC88C52
wdt:P921
wd:Q6949365
p:P698
wds:Q47631238-720A3F02-20E6-4620-944C-9A6D789FD33F
wdtn:P698
n13:26897615
wdt:P698
26897615
p:P1433
wds:Q47631238-FAF053F5-C5EE-44A9-B0EC-9ACF2DCC465E
wdt:P1433
wd:Q2312231
p:P433
wds:Q47631238-0AAB10F7-C117-40E5-8D85-A790EEC93B1C
p:P478
wds:Q47631238-5DFBFBD4-C975-4E47-B9F4-BFDFB5B6805A
wdt:P433
2
wdt:P478
34
p:P356
wds:Q47631238-DC1942AB-4A31-45A8-831C-87DFBE32CAB9
wdtn:P356
n11:S10637-016-0333-Z
wdt:P356
10.1007/S10637-016-0333-Z